For patients with prior HR+HER2- localized breast cancer currently receiving adjuvant endocrine therapy, is there a time period in which you would no longer recommend adding adjuvant abemaciclib?   

(assuming they meet MonarchE criteria)

For example, if the patient is in year 2, 3, 4, or 5 of adjuvant endocrine therapy versus 9 months out, would this change your recommendation?

Answer from: Medical Oncologist at Academic Institution